drugset / Trial / NCT01340911

A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases

NCT01340911 ↗

Phase 1 Completed 78 enrolled Sirtris, a GSK Company
RandomizedParallel-groupSingle-blindBasic science

Summary

The main purpose of the study is to see how safe SRT3025 (study drug) is when given at different doses. The study will also investigate how the study drug is taken up, metabolised (chemically broken down), distributed through the body and excreted. A further aim is to look at how taking the study drug after eating might change this process.

Timeline

Start
2011-06-03
Primary completion
2011-11-24
Completion
2011-11-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator SRT3025 Unknown 50 mg —
Comparator SRT3025 Unknown 150 mg —
Comparator SRT3025 Unknown 500 mg —
Comparator SRT3025 Unknown 1000 mg —
Comparator SRT3025 Unknown 2000 mg —
Comparator SRT3025 Unknown 3000 mg —